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The characteristics of ipsilateral breast tumour recurrences (IBTRs) relative to those of their primary tumours (PTs) remain scarcely
studied. Of 70 young (p40 years) premenopausal women with IBTRs, we studied a series of 63 with paired histological data. Median
follow-up since IBTR was 10 years. Rates of histological types, grades or hormonal receptors were not significantly different in PTs and
in IBTRs. The concordance between IBTRs and their PTs was good for histological types. IBTRs with conserved histological types
tended to occur more locally, but not significantly sooner than others. These IBTRs had good concordance for hormone receptors. In
discordant cases there were as many losses as appearances of the receptors. The concordance was weak for grades, with equivalent
numbers of IBTRs graded lower as higher than their PTs. The 10-year overall survival rate was 70%. Neither the conservation of
histological type, location, nor of the two combined were associated with deaths. Early (o2 years) IBTRs, tended to be associated
with poorer survival (HR¼2.24 (0.92–5.41); P¼0.08). IBTRs did not display features of higher aggressiveness than PTs. Neither
clinical nor histological definition of a true recurrence could be established other than the conservation of the histological type.
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Breast-conserving treatments of early stage breast cancer exposes
the patient to the risk of ipsilateral breast tumour recurrence
(IBTR). The most important prognostic factor for local recurrence
is the young age of the patient (Vrieling et al, 2003) and this
remains true among young (o40 years old), premenopausal
women treated either by surgery first (Bollet et al, 2007) or by
neoadjuvant chemotherapy (Oh et al, 2006). Many questions
remain unanswered concerning the real nature of these ipsilateral
breast tumour recurrences. We shall examine how different they
are from primary tumours and whether there are clinical or
histological factors to help distinguish between a re-growth of
malignant cells not removed by surgery and not killed by
radiotherapy (also called a true recurrence, TR) and a de novo
malignancy arising from mammary epithelial cells of residual
breast tissues (also known as new primary tumours, NP) (Haffty
et al, 1993). Some have implied that ipsilateral breast tumour
recurrences should display features of, at least as much aggres-
siveness (differentiation (Huang et al, 2002), ploidy (Haffty et al,
1993) and percentage of invasiveness (Haffty et al, 1993; Smith
et al, 2000; Huang et al, 2002)) to qualify as true recurrences. We
shall see whether biological evidence can be found to support this
definition. Finally, we shall investigate whether the characteristics
of ipsilateral breast tumour recurrences are associated with
prognosis.
PATIENTS AND METHODS
Out of a previously described series of 209 premenopausal women,
younger than 40 years old, treated at the Institut Curie between
1985 and 1995 for early breast cancers (clinical T1-2, N0-1 ; Sobin
and Wittekind, 2002) with primary breast-conserving surgery and
followed over a long period (median follow-up of 12 years), 70
patients were diagnosed with local recurrences (Bollet et al, 2007).
We consider here a group of 63 patients for whom histological and
immuno-histochemical data were available for both the primary
tumour and the local relapse (some patients were not treated for
their local relapse at the Institut Curie). We report here a study
about the similarities between primary breast cancers and their
local relapses in terms of histological and immuno-histochemical
features according to the site of relapse and the time-lapse before
relapse. Median age at diagnosis was 36 years (23–40) with 57% of
patients (36 patients) 35 year old or younger and 43% between 36
and 39 years old (27 patients). All patients were premenopausal at
the time of the initial treatment. A family history indicating that at
least one first- or second-degree relative with a history of breast
cancer was present in 71% of patients (45 patients), absent in 27%
(17 patients) and unknown in 2% (1 patient).
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(Sobin and Wittekind, 2002) was T1 for 70% (44 patients) and T2
for 30% (19 patients). N stage was N0 for 73% (50 patients), N1 for
21 % (13 patients).
All the specimens were reviewed by the same qualified breast
pathologist (BSZ). Histological classification of the infiltrating
carcinomas was done according to the World Health Organization
criteria and histological grades were scored according to Elston
and Ellis (1991). The mitotic index was determined according to
the number of mitoses per 10 high power fields (each field
corresponded to a surface of 3.3mm
2), as low when o11,
moderate when (11–22) and high when 422 (Vincent-Salomon
et al, 2004). Hormonal receptors were positive if they showed
staining of either oestradiol receptors (ER) or progesterone
receptors in at least 10% of invasive tumour cells by immuno-
histochemistry.
Treatments of the primary tumour consisted, for all patients, in
surgery with breast-conserving procedures as the first treatment.
The quality of the surgical margin was stated as wide (43mm) in
40 patients (63%), close (p3mm) in 14 (22%), involved with
ductal carcinoma in situ in four (6%), involved with invasive
carcinoma in five (8%). The reasons for the absence of re-excision
were not always specified. When they were, it was because of the
patient’s choice not to undergo a new surgical procedure that
could have been a mastectomy.
All patients received post-operative radiotherapy with a median
dose of 54Gy (45–62) to the breast. A boost to the tumorectomy
bed was performed for 68% (36 patients) of the women with a
median dose of 16Gy (2–25). The median total dose to the
tumorectomy bed was 62Gy (52–76). There was no protocol to
boost all young patients with negative surgical margins at that time
and some of the patients reported in this series were accrued in the
EORTC boost trial that randomised from 1989 to 1996 between
boost and no boost (Bartelink et al, 2001; Vrieling et al, 2003;
Antonini et al, 2006). In the case of positive surgical margins, a
radiotherapy boost of generally 20–28Gy was added to the whole-
breast irradiation. For patients who were not participating in the
European Organisation for Research and Treatment of Cancer
randomised trial, a boost of 10–16Gy was added in the case of
aggressive histological features (unsatisfactory margins, high
histological grade, high proliferation index, absence of hormone
receptors).
Systemic treatments were given in 30% (63 patients) of the
women. At the time of treatment, the protocol for premenopausal
women consisted of anthracycline-based polychemotherapy
(usually six cycles of 5-fluorouracil, doxorubicin, cyclophospha-
mide) without hormone therapy.
Statistics
Comparisons of pathological characteristics between primary
tumours and ipsilateral breast tumour recurrences were performed
by McNemar w
2 paired analysis that tests the hypothesis that,
among discordant cases, the evolution was more often of one kind
than another. For instance, when applied to oestradiol receptors,
there was a significant difference between the numbers of cases
with a loss of ER and those with an appearance of ER (ER  in PT
and ERþ in IBTR). When the analysed pathological feature had
more than two classes, analysis was downsized to a 2 2 table.
Differences in qualitative assessments between the two groups of
patients were tested by Fisher’s exact test or the w
2-test, while
differences in quantitative measurements were tested by either the
Student’s t-test or Kruskal–Wallis test (depending on the
distribution characteristics). Median follow-up was calculated
using the reverse Kaplan–Meier estimator (Kaplan and Meier,
1958). Overall survival was defined as the lapse of time from the
date of ipsilateral breast tumour recurrence to the date of death.
Distant relapse-free survival was defined from the date of
ipsilateral breast tumour recurrence to the date of diagnosis of
distant relapse or death. Overall and distant relapse-free survivals
were estimated with the Kaplan–Meier technique (Kaplan and
Meier, 1958). Cox proportional hazards regression models were
used to estimate the effects of the type of ipsilateral breast tumour
recurrences on prognosis. Estimates of effects are presented as
hazard ratios with their associated 95% confidence intervals. A
higher hazard ratio is associated with an increased risk of event
(death or metastasis).
All concordance tests were calculated according to Cohen’s
Kappa. A kappa value o0.5 is considered weak, 0.5–0.7 fair, and
40.7 is considered very good concordance. The level of statistical
significance was 0.05. The concordance tests were always assessed
for the whole group of patients and in the two different
subpopulations according to the lapse of time of occurrence of
the local relapse from the first treatment of the primary tumour
(within the first 5 years or later) or to the site of the local
recurrence with respect to the primary tumour (same quadrant or
different quadrant).
RESULTS
Median time-lapse between the primary tumour and its ipsilateral
breast tumour recurrence was 43 months (3–158). Median follow-
up since ipsilateral breast tumour recurrence was 10 years (1–18).
Histological details of both the primary tumour and its
ipsilateral breast tumour recurrence are given in Table 1. In
summary, the rates of histological types, grades (and their
components) or hormonal receptors were not statistically different
in the primary tumours from the ipsilateral breast tumour
recurrences.
Ipsilateral breast tumour recurrences occurred in the index
quadrant, the one where the primary tumour had arisen, in 70%
(44 patients), in a different quadrant in 27% (17 patients) and in
3% of cases (two patients) the relative locations were unknown.
The mean time-lapse before occurrence of the ipsilateral breast
tumour recurrence was not significantly different in the case of a
recurrence at the index quadrant or not (respectively 55 vs 53
months; P¼0.8). The rate of ipsilateral breast tumour recurrences
occurring within the first 2 years was not significantly higher for
those that had recurred at the index quadrant than for the others
(18 vs 12%; P¼0.72).
Concordance tests
Histological types of infiltrating carcinomas As represented in
Table 2 there was a good concordance with 94% of cases (59
patients out of 63) with conservation of the histological types k
0.72. The ipsilateral breast tumours that shared their primary
tumour’s histological types tended to occur more locally than
those with a different histological type (rate of recurrence in the
index quadrant of 75 vs 25%; P¼0.07) but not statistically sooner
(median time-lapse before occurrence of 41 vs 71 months;
P¼0.36).
In 45 cases (71%) ipsilateral breast tumour recurrences shared
both the same histological type and the same location (index
quadrant) with their primary tumours. These ipsilateral breast
tumour recurrences did not occur significantly sooner than the
others (median time lapse of 38 vs 54 months; P¼0.34).
In 33 cases out of 61 cases for which data were available (52%),
the ipsilateral breast tumour recurrences had occurred not only
with a conserved histological type, but also with features of equal
or lesser differentiation (loss of hazard ratio, higher histological
grade) than their primary tumours. These cases did not occur
significantly neither more locally (rate of recurrence in the index
quadrant of 81 vs 61%; P¼0.15) nor sooner (median time lapse of
37 vs 51 months; P¼0.19) than others.
IBTR vs primary breast cancer
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pairs) As represented in Table 3, provided that only conserved
histological types were studied, the concordance between primary
tumours and their local recurrences was weak for progesterone
(k 0.47), fair for oestradiol (k 0.52) and good for hormone (k 0.85)
receptors. In the case of discordant cases, there was no statistically
significant difference between changes, whether loss or appearance
of the receptors.
Of the 54 pairs for which both the primary tumours and the
ipsilateral breast tumour recurrences were histologically graded,
the grades remained the same in 21 patients (39%), weak
concordance (k 0.03). There was no statistically significant
difference between patients for whom the IBTR was graded higher
and those for whom it was graded lower than the primary tumour
(17 vs 16 patients; P¼0.86).
Prognostic implications for the conservation of location,
histological type or both on overall survival
Rates of 5- and 10-year overall survivals were respectively 79%
(69–90) and 70% (59–84).
Neither the conservation of the histological type in the ipsilateral
breast tumour recurrence (hazard ratio¼1.27 (0.29–5.56);
P¼0.75), nor the conservation of location with ipsilateral breast
tumour recurrence occurring at the index quadrant (hazard
ratio¼1.13 (0.43–2.95); P¼0.8), nor the two combined, that is
conservation of both histological type and location versus the
others (hazard ratio¼1.07 (0.43–2.7); P¼0.88) nor those with
conserved histological types and equal or lesser differentiation
(hazard ratio¼2.08 (0.85–5.2); P¼0.11) were statistically asso-
ciated with deaths. Early ipsilateral breast tumour recurrences,
defined as occurring within the first 2 years, tended to be
associated with a higher rate of death (hazard ratio¼2.24 (0.92–
5.41); P¼0.08) than late recurrences. When comparing both the
tumours and their ipsilateral breast tumour recurrences according
to the free interval with a cutoff at 2 years, the only statistically
significant differences were that primary tumours associated with
early ipsilateral breast tumour recurrences (IBTRs) were more
proliferating than the others and that early IBTRs (occurring
within the first 2 years) had a higher degree of nuclear
polymorphism than late IBTRs, as shown in Table 4.
DISCUSSION
The occurrence of an ipsilateral breast tumour recurrence is
associated with poor prognosis because of the potential risk of
lethality from its propensity to yield metastases (Clarke et al,
2005).
In this study of a homogeneous group of young (p40 years old)
patients, we did not find that, per se, ipsilateral breast tumour
recurrences display features of higher aggressiveness than primary
tumours (Table 1). All features were highly comparable between
the two groups of tumours.
In some cases, the occurrence of an ipsilateral breast tumour
recurrence can also reflect the evolution of the primary tumour
and thus its resistance to the adjuvant therapies used in the first
instance: that is radiotherapy with or without systemic treatments.
These ipsilateral breast tumour recurrences are also called true
recurrences, in opposition to new primaries. Their definition
according to clinical and histological criteria remains a wild
dream. All authors agree on a basic definition of a new primary
that is, an ipsilateral breast tumour recurrence with a different
histological type from its primary tumour (Haffty et al, 1993;
Touboul et al, 1999; Smith et al, 2000; Huang et al, 2002; Komoike
et al, 2005). Our series showed a good concordance of the
histological type in the ipsilateral breast tumour recurrence.
Most authors have also proposed that location would help
distinguish the two - with ipsilateral breast tumour recurrences
occurring away from the index quadrant more prone to be new
primaries (Fisher et al, 1986; Haffty et al, 1993; Smith et al, 2000;
Huang et al, 2002). This was confirmed in our series where
ipsilateral breast tumour recurrences that had conserved their
Table 2 Comparison between pathological characteristics between PT
and their ipsilateral breast tumour recurrences
Ipsilateral breast tumour recurrences
Histological type
of the infiltrating
carcinomas paired v
2
(McNemar test)¼1
j¼0.72 Ductal Lobular Mucinous
Primary
Ductal 53 2 0
Lobular 0 4 0
Tumours
Mucinous 0 0 2
Other 2 0 0
PT¼primary tumours.
Table 1 Patients’ and tumours’ characteristics
Primary tumour IBTR
N % N % P
Infiltrating carcinoma d DM¼0D M ¼01
Ductal 55 87 55 87
Lobular 4 6 6 10
Other 4 6 2 3
Histological grade DM¼4D M ¼31
12 2 3 7 1 6 2 7
22 3 3 9 3 5 5 8
31 4 2 4 9 1 5
Tubule formation DM¼01
1.2 15 24 16 25
34 8 7 6 4 7 7 5
Nuclear polymorphism DM¼0D M ¼01
11 0 1 6 9 1 4
24 2 6 7 4 3 6 8
31 1 1 7 1 1 1 7
Mitoses per 10 HPF DM¼4D M ¼3 0.48
[0-10] 40 68 40 67
[11-21] 11 19 14 23
X22 8 14 6 10
Oestradiol receptors DM¼0D M ¼0 0.43
Positive (X10 %) 41 65 45 71
Negative 22 35 18 29
Progesterone receptors DM¼0D M ¼01
Positive (X10%) 42 67 41 65
Negative 21 33 22 35
Hormone receptors 1
Positive (either ER or PR X10 %) 49 78 50 79
Negative (both ER and PR o10%) 14 22 13 21
ER¼oestradiol receptors; HPF=high power field; IBTR¼ipsilateral breast tumour
recurrences; PR¼progesterone receptor.
IBTR vs primary breast cancer
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sprimary tumours’ histological types tended to arise more often in
the index quadrant than others. When addressing only ipsilateral
breast tumour recurrences with conserved histological types, we
showed a good concordance with their primary tumours in terms
of hormonal receptors but the absence of any concordance in
terms of histological grade and its components. Bearing in mind
the inter-observer disagreement (Frierson et al, 1995; Robbins
et al, 1995), there is always the concern that it could reflect an
intra-observer variability in the definition of the histological grade.
The question remains whether the assumption that the definition of
true recurrences could rely on the possibility that true recurrences
show features of lesser differentiation than their primary tumours.
To address it, we first looked at discordant cases in terms of
histological grade. There was no sign that the evolution was more
prone to be towards more aggressiveness than less. Secondly,
ipsilateral breast tumour recurrences with conserved histological
types with features of equal or lesser differentiation than their
primary tumours did not occur significantly more locally.
Table 3 Comparison of pathological characteristics between PT and their ipsilateral breast tumour recurrences provided that they share the same
histological types (59 pairs of PT/IBTR)
Ipsilateral breast tumour recurrence
Oestradiol receptors McNemar’s test¼0.39 j¼0.52 Negative Positive
Primary tumour
Negative 12 8
Positive 43 5
Ipsilateral breast tumour recurrence
Progesterone receptors McNemar’s test¼1 j¼0.47 Negative Positive
Primary tumour
Negative 13 7
Positive 73 2
Ipsilateral breast tumour recurrence
Hormone receptors McNemar’s test¼1 j¼0.85 Negative Positive
Primary tumour
Negative 11 2
Positive 14 5
Ipsilateral breast tumour recurrence
Histological grade (DM¼5) McNemar’s test¼0.86 j¼0.03 Grade 1 Grade 2 Grade 3
Primary tumour
Grade 1 71 2 1
Grade 2 71 1 4
Grade 3 09 3
Ipsilateral breast tumour recurrence
Mitotic index (DM¼5) McNemar’s test¼0.63 j¼0.33 Low Moderate High
Primary tumour
Low 31 3 3
Moderate 45 1
High 33 1
Ipsilateral breast tumour recurrence
Nuclear polymorphism (DM¼0) McNemar’s test¼0.61 j¼0.33 Low Moderate High
Primary tumour
Low 53 1
Moderate 23 4 5
High 04 5
Ipsilateral breast tumour recurrence
Tubule formation (DM¼0) McNemar’s test¼1 j¼0.12 Low Moderate High
Primary tumour
Low 02 1
Moderate 04 8
High 19 3 4
IBTR vs primary breast cancer
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recurrences display at most equal but not higher differentiation
than their primaries) are twofold. First, some adjuvant treatments
such as chemotherapy could electively kill the most undiffer-
entiated clones from the primary tumour and thus select those of
higher differentiation, resistant to chemotherapy. The equivalent
has already been shown in some studies where either the clonal
heterogeneity found in the primary tumours (Teixeira et al, 1996)
or the amount of their chromosomal alterations (Kuukasjarvi et al,
1997) were reduced in their metastases. Second, the chronological
order of the discovery of two breast cancers with clonal homology
does not forcefully reflect the paternity of the first over the second
because a tumour with few alterations can be occult for years
following the removal of a more deranged derivative. This has been
inferred in the case of bladder cancer from the study of several
tumours removed from the same patient over a long period of time
(van Tilborg et al, 2000). Beside these arguments, the absence of a
trend for a progression of grade between different stages of the
breast cancer has already been shown by Millis et al (1998) both
from ductal carcinoma in-situ to invasive ductal carcinoma and
from invasive ductal carcinoma to axillary lymph nodes, local
(ipsilateral breast tumour recurrences excluded) or distant
recurrences.
Contrary to others (Haffty et al, 1993; Goldstein et al, 2005;
Vicini et al, 2007), we found no indication that tumours more
prone to be true recurrences because of conserved histological
type, location or both, recur sooner or are deadlier than the others.
The same applied to the conservation of histological type and
features of equal or lesser differentiation. On the other hand, we
confirmed the notion that early recurrences, that is occurring
within the first 2 years, are associated with more deaths than late
ones (Fourquet et al, 1989; Fisher et al, 1991; Whelan et al, 1994;
Veronesi et al, 1995; Haffty et al, 1996; Fredriksson et al, 2002). In
our study the group of patients with early recurrences had primary
tumours significantly more proliferating and ipsilateral breast
tumour recurrences with a higher degree of nuclear polymorphism
than the group of patients with late recurrences.
The main drawback of this study is the relatively small size of
our series under-powering the possibility of revealing real
associations between the assessed factors. We conclude however
that the definition of true recurrences according to clinical and
histological criteria should rely solely on the conservation of the
histological type with the added information brought by the
location. There is no indication that true recurrences should have
features of equal or lesser differentiation than their primary
tumours.
However, because of the overwhelmingly high rate of the ductal
histological type among breast cancers, there is need to improve
the definition of true recurrences by using new biological tools of
clonal relation such as pan-genomic profiles (Waldman et al,
Table 4 Comparison of pathological features of primary tumours and of IBTR according to the free interval between the two (within or after 2 years)
Primary tumour IBTR
Early (N¼52) Late (N¼11) Early (N¼52) Late (N¼11)
N % N % PN % N % P
Infiltrating carcinoma 0.15 0.6
Ductal 47 90 8 73 46 88 9 82
Lobular 2 4 2 18 4 8 2 18
Other 3 6 1 9 2 4 0 0
Histological grade 0.18 0.2
1 20 41 2 20 15 30 1 10
2 20 41 3 30 29 58 6 60
3 9 18 5 50 6 12 3 30
Tubule formation 0.06 0.8
1.2 15 29 0 0 14 27 2 18
3 37 71 11 100 38 73 9 82
Nuclear polymorphism 0.13 0.005
1 8 15 2 18 8 15 1 9
2 37 71 5 45 39 75 4 36
3 7 13 4 36 5 10 6 55
Mitoses per 10 HPF
a 0.02 0.15
[0–10] 37 76 3 30 36 72 4 40
[11–21] 7 14 4 40 10 20 4 40
X22 5 10 3 30 4 8 2 20
Oestradiol receptors 0.5 0.3
Positive 35 67 6 55 39 75 6 55
Negative 17 33 5 45 13 25 5 45
Progesterone receptors 0.8 0.18
Positive 34 65 8 73 36 69 5 45
Negative 18 35 3 27 16 31 6 55
Hormone receptors 0.7 0.22
Positive 41 79 8 73 43 83 7 64
Negative 11 21 3 27 9 17 4 36
IBTR¼ipsilateral breast tumour recurrences.
aHPF¼high power field. Bold values are statistically significant P-values.
IBTR vs primary breast cancer
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s2000), loss of heterozygosity (Schlechter et al, 2004; Vicini et al,
2007), p53 mutation analysis (van der Sijp et al, 2002) or the
inactivation of the X chromosome (Shibata et al, 1996). Caution is
however still needed as some of these techniques conclude that
only 65% of clonally related ipsilateral breast tumour recurrences
have the same histological types as their primary tumours (Vicini
et al, 2007).
We hope that a better distinction of true recurrences will open
new perspectives. So far, very little is known about the differential
or similarity of the pan-genomic expression or nature of both new
primaries and IBTRs. Kreike et al (2006) reported a gene
expression analysis of 18000 cDNAs on nine pairs of primary
breast cancer with their ipsilateral breast recurrences in women
who were younger than 51 years old at the time of their initial
breast-conserving therapy. Paired-data analysis showed no set of
genes that was consistently different in expression between
primary tumours and local recurrences. Better focusing on true
recurrences only and comparing them in detail with their primary
tumours, could hopefully reveal possible clonal selections of cells
endowed with attributes of either radio-resistance or aggressive-
ness. Another route that has still scarcely been explored is the
search for a transcriptomic signature to predict the risk of local
recurrence after breast-conserving treatment (Kreike et al, 2006;
Nuyten et al, 2006). Here also, a better distinction between new
primaries and true recurrences is needed to perform a supervised
study according to the occurrence of true recurrences only and not
of all ipsilateral breast tumour recurrences.
CONCLUSION
Ipsilateral breast tumour recurrences did not display features of
higher aggressiveness than primary tumours. There was no
indication that tumours more prone to be true recurrences
because of conserved histological type, location or both, recur
sooner or are deadlier than the others. No clinical nor histological
definition of a true recurrence could be established other than the
conservation of the histological type.
ACKNOWLEDGEMENTS
We thank all the members of the Groupe Sein at the Institut Curie
for their participation in the care of the patients. We also thank
Danie `le Chazal and Claudie Gallet for processing the pathological
specimens and Chantal Gautier for managing the data. This study
was financed by a grant from the Comite ´ de Paris de la Ligue
Nationale de Lutte contre le Cancer 75/00-RS/41.
REFERENCES
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, den Bogaert
WV, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M,
Hart G, Bartelink H (2006) Effect of age and radiation dose on local
control after breast conserving treatment: EORTC trial 22881–10882.
Radiother Oncol 82: 265–271
Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W,
Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L,
Pierart M (2001) Recurrence rates after treatment of breast cancer with
standard radiotherapy with or without additional radiation. N Engl J Med
345: 1378–1387
Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A,
Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R,
Fourquet A (2007) Age remains the first prognostic factor for loco-
regional breast cancer recurrence in young (o40 years) women treated
with breast conserving surgery first. Radiother Oncol 82: 272–280
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J,
Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R,
Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the
extent of surgery for early breast cancer on local recurrence and 15-year
survival: an overview of the randomised trials. Lancet 366: 2087–2106
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer.
I. The value of histological grade in breast cancer: experience from a
large study with long-term follow-up. Histopathology 19: 403–410
Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N,
Mamounas EP, Deutsch M, Margolese R (1991) Significance of ipsilateral
breast tumour recurrence after lumpectomy. Lancet 338: 327–331
Fisher ER, Sass R, Fisher B, Gregorio R, Brown R, Wickerham L (1986)
Pathologic findings from the National Surgical Adjuvant Breast Project
(protocol 6). II. Relation of local breast recurrence to multicentricity.
Cancer 57: 1717–1724
Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand JC, Vilcoq
JR (1989) Prognostic factors of breast recurrence in the conservative
management of early breast cancer: a 25-year follow-up. Int J Radiat
Oncol Biol Phys 17: 719–725
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjovall M,
Fornander T, Holmqvist M, Holmberg L, Frisell J (2002) Local recurrence
in the breast after conservative surgery – a study of prognosis and
prognostic factors in 391 women. Eur J Cancer 38: 1860–1870
Frierson Jr HF, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ,
Boyd JC, Wilbur DC (1995) Interobserver reproducibility of the
Nottingham modification of the Bloom and Richardson histologic
grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol
103: 195–198
Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kraus D, Kestin LL
(2005) Molecular clonality determination of ipsilateral recurrence of
invasive breast carcinomas after breast-conserving therapy: comparison
with clinical and biologic factors. Am J Clin Pathol 123: 679–689
Haffty BG, Carter D, Flynn SD, Fischer DB, Brash DE, Simons J, Ziegler AM,
Fischer JJ (1993) Local recurrence versus new primary: clinical analysis
of 82 breast relapses and potential applications for genetic fingerprinting.
Int J Radiat Oncol Biol Phys 27: 575–583
Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C (1996)
Ipsilateral breast tumor recurrence as a predictor of distant disease:
implications for systemic therapy at the time of local relapse. J Clin Oncol
14: 52–57
Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC,
Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA,
Hunt KK (2002) Classifying local disease recurrences after breast
conservation therapy based on location and histology: new primary
tumors have more favorable outcomes than true local disease
recurrences. Cancer 95: 2059–2067
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete
observation. J Am Stat Assoc 53: 457–481
Komoike Y, Akiyama F, Iino Y, Ikeda T, Tanaka-Akashi S, Ohsumi S,
Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T,
Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M,
Tsukuma H, Inaji H (2005) Analysis of ipsilateral breast tumor
recurrences after breast-conserving treatment based on the classification
of true recurrences and new primary tumors. Breast Cancer 12: 104–111
Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de
Vijver MJ (2006) Gene expression profiles of primary breast carcinomas
from patients at high risk for local recurrence after breast-conserving
therapy. Clin Cancer Res 12: 5705–5712
Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N,
Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J (1997) Genetic
heterogeneity and clonal evolution underlying development of asyn-
chronous metastasis in human breast cancer. Cancer Res 57: 1597–1604
Millis RR, Barnes DM, Lampejo OT, Egan MK, Smith P (1998) Tumour
grade does not change between primary and recurrent mammary
carcinoma. Eur J Cancer 34: 548–553
Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ,
Bartelink H, Brown PO, Chang HY, van de Vijver MJ (2006) Predicting a
local recurrence after breast-conserving therapy by gene expression
profiling. Breast Cancer Res 8: R62
Oh JL, Bonnen M, Outlaw ED, Schechter NR, Perkins GH, Strom EA,
Babiera G, Oswald MJ, Allen PK, Thames HD, Buchholz TA (2006) The
IBTR vs primary breast cancer
B Sigal-Zafrani et al
1051
British Journal of Cancer (2007) 97(8), 1046–1052 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
simpact of young age on locoregional recurrence after doxorubicin-based
breast conservation therapy in patients 40 years old or younger: how
young is ‘young’? Int J Radiat Oncol Biol Phys 65: 1345–1352
Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I,
Elston C (1995) Histological grading of breast carcinomas : a study of
interobserver agreement. Hum Pathol 26: 873–879
Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las
Morenas A, Rosenberg CL (2004) Quantitative DNA fingerprinting may
distinguish new primary breast cancer from disease recurrence. J Clin
Oncol 22: 1830–1838
Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA, Ross RK (1996)
Clonal analysis of bilateral breast cancer. Clin Cancer Res 2: 743–748
Smith TE, Lee D, Turner BC, Carter D, Haffty BG (2000) True recurrence vs
new primary ipsilateral breast tumor relapse: an analysis of clinical and
pathologic differences and their implications in natural history,
prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys
48: 1281–1289
Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours.
New-York: Wiley-Liss
Teixeira MR, Pandis N, Bardi G, Andersen JA, Heim S (1996) Karyotypic
comparisons of multiple tumorous and macroscopically normal
surrounding tissue samples from patients with breast cancer. Cancer
Res 56: 855–859
Touboul E, Buffat L, Belkacemi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C,
Huart J, Lotz JP, Antoine M, Pene F, Blondon J, Izrael V, Laugier A,
Schlienger M, Housset M (1999) Local recurrences and distant
metastases after breast-conserving surgery and radiation therapy for
early breast cancer. Int J Radiat Oncol Biol Phys 43: 25–38
van der Sijp JR, van Meerbeeck JP, Maat AP, Zondervan PE, Sleddens HF,
van Geel AN, Eggermont AM, Dinjens WN (2002) Determination of the
molecular relationship between multiple tumors within one patient is of
clinical importance. J Clin Oncol 20: 1105–1114
van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH,
Zwarthoff EC (2000) Molecular evolution of multiple recurrent cancers of
the bladder. Hum Mol Genet 9: 2973–2980
Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M,
Luini A, Merson M, Saccozzi R, Rilke F, Salvadori B (1995) Local
recurrences and distant metastases after conservative breast cancer
treatments: partly independent events. J Natl Cancer Inst 87: 19–27
Vicini FA, Antonucci JV, Goldstein N, Wallace M, Kestin L, Krauss D,
Kunzmann J, Gilbert S, Schell S (2007) The use of molecular assays to
establish definitively the clonality of ipsilateral breast tumor recurrences
and patterns of in-breast failure in patients with early-stage breast cancer
treated with breast-conserving therapy. Cancer 109: 1264–1272
Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B,
Freneaux P, Rosty C, Nos C, Campana F, Klijanienko J, Al Ghuzlan A,
Sastre-Garau X (2004) Proliferation markers predictive of the patholo-
gical response and disease outcome of patients with breast carcinomas
treated by anthracycline-based preoperative chemotherapy. Eur J Cancer
40: 1502–1508
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing
Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den
Bogaert W, Bartelink H (2003) Can patient-, treatment- and pathology-
related characteristics explain the high local recurrence rate following
breast-conserving therapy in young patients? Eur J Cancer 39: 932–944
Waldman FM, DeVries S, Chew KL, Moore II DH, Kerlikowske K, Ljung BM
(2000) Chromosomal alterations in ductal carcinomas in situ and their in
situ recurrences. J Natl Cancer Inst 92: 313–320
Whelan T, Clark R, Roberts R, Levine M, Foster G (1994) Ipsilateral breast
tumor recurrence postlumpectomy is predictive of subsequent mortality:
results from a randomized trial. Investigators of the Ontario Clinical
Oncology Group. Int J Radiat Oncol Biol Phys 30: 11–16
IBTR vs primary breast cancer
B Sigal-Zafrani et al
1052
British Journal of Cancer (2007) 97(8), 1046–1052 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s